microbiome platform News
-
Notitia Biotechnologies receives approval from FDA for phase 2A clinical trial in diabetic & prediabetic patients
Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient's gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. Notitia has secured funding for a Phase 2a ...
-
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
April 22, 2022 at 8:00 AM EDT NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 22, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview with ...
-
Notitia Biotechnologies Develops Revolutionary Foundation Guild Lbp for Patients With Diabetic Kidney Disease (DKD)
Notitia Biotechnologies Company has developed a ground-breaking live biotherapeutic product (LBP) for patients with early-stage and end-stage diabetic kidney disease (DKD) patients. The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format. Notitia is preparing the Investigational New Drug (IND) ...
-
Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced they are entering a strategic collaboration with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) to identify microbiome biomarkers associated with clinical response for their lead program in ...
-
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an ...
-
DermBiont Announces Acquisition of SeylanMED to Expand its Portfolio of Targeted Topical Therapeutics Treating Skin Diseases at Their Root Cause
BOSTON, MA, October 21, 2020 – DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. “This strategic acquisition delivers multi-factorial value,” said Karl Beutner, MD, PhD, Co-founder, CEO, and CMO of DermBiont. “It expands ...
-
Bio-Me and Siolta Therapeutics to collaborate on developing microbiome-based pediatric allergy and asthma test
Microbiome Dx company Bio-Me and Siolta Therapeutics today announced that they have entered into a collaboration and marketing agreement. Under the agreement, Siolta will provide both samples and insights into key criteria for Bio-Me to develop a rapid, detailed and comprehensive diagnostic test for infants at risk of developing allergy and asthma. The test will be offered to parents of ...
By Bio-Me
-
Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) ...
-
Bio-Me and Siolta Therapeutics to collaborate on developing microbiome-based pediatric allergy and asthma test
Microbiome Dx company Bio-Me and Siolta Therapeutics today announced that they have entered into a collaboration and marketing agreement. Under the agreement, Siolta will provide both samples and insights into key criteria for Bio-Me to develop a rapid, detailed and comprehensive diagnostic test for infants at risk of developing allergy and asthma. The test will be offered to parents of ...
-
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic ...
-
Symberix Awarded Multiple Grants from National Institutes of Health to Expand Platform of Microbiome-Targeted Drugs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational ...
-
Bio-Me Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the ...
By Bio-Me
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
-
Testing of a Drug Panel for effects on the gut Microbiome using RapidAIM
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs. ...
-
Official Opening of Service Laboratory
Bio-Me, a pioneer in rapid gut microbiome analysis is announcing the opening of its gut microbiome analysis service laboratory. This will enable the Research & Development departments worldwide to access their Precision Microbiome Profiling (PMP™) platform. The service laboratory is located at the Oslo’s Science Park’s premier lab sharing facility, the ShareLab. The lab ...
By Bio-Me
-
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. This ODD designation will provide SFA ...
-
Microvi and Nexilico Develop Powerful Computational Platform for Gut Microbiome funded by NIH
Under a National Institute of Health (NIH) grant awarded by the National Institute of General Medical Sciences (NIGMS), Microvi, Nexilico, and their research partners have developed a first-of-its-kind predictive computational platform focused on the gut microbiome and its interaction with therapeutics. The in silico platform reduces the cost and timeframe of drug development by reducing the ...
-
Shoreline Biome Announces Name Change to Intus Biosciences
Shoreline Biome, the developer of the industry-leading Titan-1™ microbiome research, discovery and testing platform, announced today that it has changed its name to Intus Biosciences. Intus—a Latin word for “inside”— reflects the company’s focus on making advances in health and wellbeing by working inside the bacterial microbiome. The change marks Intus ...
-
Microbiotica Moves Into New Building at Chesterford Research Park
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has finalised its move to purpose-configured facilities at Chesterford Research Park, to accommodate its long-term growth requirements. The Company’s operations were previously split between the Sulston Building and the BioData Innovation Centre at the Wellcome Genome Campus, before ...
-
Intus Bio’s Software Update Enables High-throughput Microbiome Profiling of Known and Unknown Microbial Strains
Intus Biosciences, a microbiome research company with multi-platform, easy to use, ‘Sample-to-Answer’ products for characterizing microbiome populations down to the strain level, announces a significant update to its SBanalyzer software. Intus Biosciences SBanalyzer software enables discovery of never before detected species and strains from microbiome samples. In addition, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you